Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DeepMatter Appoints Industry Advisors

16 Dec 2019 07:00

RNS Number : 8960W
DeepMatter Group PLC
16 December 2019
 

DeepMatter Group plc

("DeepMatter", the "Company" or "the Group")

 

DeepMatter Appoints Industry Advisors

DeepMatter strengthens its depth of knowledge and industry links in Research & Medicinal Chemistry, Process Chemistry and Automation

 

16 December 2019 - DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, is delighted to welcome three leading sector figures as industry advisors on its commercial roll-out of DigitalGlassware™. The advisors bring in-depth knowledge in research & medicinal chemistry, process chemistry and industrially focused closed-loop robotics and automation, all target industries for DigitalGlassware, the Company's innovative cloud-based digital chemistry platform that brings recordability, reproducibility and shareability to the lab.

 

The advisors will contribute to the ongoing development of the DigitalGlassware™ strategic roadmap and are as follows:

 

·; Dr Richard Bourne - a leading academic in Process Chemistry. Richard is Associate Professor at the University of Leeds based at the Institute of Process Research and Development, working on rapid process development and continuous flow chemistry. In November 2019, he was announced as a new Royal Academy of Engineering Senior Research Fellow in Digital Manufacturing and Discovery of Pharmaceuticals.

·; Dr John Harris - a pharmaceutical industry consultant with a wealth of research chemistry knowledge and expertise. John was previously Head of the Wellcome Foundation's UK cardiovascular therapeutic area and founder of BioFocus, a highly successful early-stage CRO, now part of the Charles River organisation.

·; Dr David M Parry - an experienced synthetic chemist, with a track record of delivering complex projects within the pharma and biotech sectors. David built and ran a business focused on automated medicinal chemistry, where compounds would be synthesised, then tested in a primary assay on the same platforms, with the results fed back into the software to inform the next round of automated synthesis.

 

Mark Warne, Chief Executive Officer of DeepMatter, commented:

"We believe DigitalGlassware™ has the opportunity to sit at the heart of the digitisation of chemistry, enabling chemists to produce better molecules, faster and ultimately cheaper. We are delighted to welcome Richard, John and David to the DigitalGlassware™ team, each bringing valuable insight from their three areas of specialism. Their expertise will help ensure the platform meets and integrates the needs of these key disciplines, assisting us in the commercial roll-out of our innovative cloud-based digital chemistry platform."

For more information, please contact:

DeepMatter Group plc

T: 0141 548 8156

Mark Warne, Chief Executive Officer

 

 

 

 

Shore Capital (Nominated Adviser and Broker)

 

T: 020 7408 4050

Tom Griffiths

David Coaten

 

 

 

Alma PR

Caroline Forde

Jessica Joynson

Kieran Breheny

 

T: 020 3405 0205

deepmatter@almapr.co.uk

 

About DeepMatter Group plc

 

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors.

 

The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.

 

Visit: www.deepmatter.io and follow @deepmattergroup

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAMMMMZNFZGLZM
Date   Source Headline
25th Jul 20084:44 pmRNSResult of AGM
30th Jun 20087:00 amRNSAudited Final Results
4th Jun 200812:50 pmRNSCollaborative Research and De
19th May 20082:07 pmRNSChange of Company Secretary a
15th Apr 200810:47 amRNSJoint Development Agreement
7th Apr 20083:52 pmRNSBusiness Update
28th Mar 200812:36 pmRNSHolding(s) in Company
17th Mar 20082:00 pmRNSHolding(s) in Company
5th Mar 20085:22 pmRNSAward of Share Options-Amend
3rd Mar 20081:23 pmRNSAward of Share Options
27th Feb 20087:01 amRNSAppointment of Director
11th Feb 200811:46 amRNSHolding(s) in Company
16th Jan 20081:52 pmRNSChange of Accounting Ref Date
10th Jan 200810:48 amRNSHolding(s) in Company
8th Jan 200811:46 amRNSHolding(s) in Company
31st Dec 20078:00 amRNSAdmission to AIM
27th Dec 200712:11 pmRNSHolding(s) in Company
21st Dec 20072:46 pmRNSGeneral Meeting
19th Dec 20078:00 amRNSShort Notice General Meeting
13th Dec 20072:36 pmRNSSchedule 1 - Kanyon plc
13th Dec 20071:39 pmRNSAdmission Document
12th Dec 20076:31 pmRNSAcquisition
25th Oct 20077:01 amRNSInterim Results
17th Aug 20077:01 amRNSAIM Rule 26 Website
29th Jun 20079:00 amRNSTotal Voting Rights
3rd May 200712:37 pmRNSAppointment of Directors
30th Apr 200710:15 amRNSEGM Statement
30th Apr 200710:08 amRNSAGM Statement
4th Apr 20072:48 pmRNSFinal Results
28th Mar 20071:44 pmRNSAcquisition
20th Dec 200611:53 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.